27 Nov 2009 Dar es Salaam 1 CEM analyses. 27 Nov 2009 2Dar es Salaam.

Slides:



Advertisements
Similar presentations
Understanding real research 3. Assessment of risk.
Advertisements

Critical Appraisal for MRCGP Jim McMorran Coventry GP GP trainer Editor GPnotebook (
Journal Club Alcohol and Health: Current Evidence March-April 2007.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2009.
Measures of Disease Association Measuring occurrence of new outcome events can be an aim by itself, but usually we want to look at the relationship between.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2011.
Simple Short Reports #4 Mummy’s curse Dr. Craig Jackson Senior Lecturer in Health Psychology School of Health and Policy Studies Faculty of Health & Community.
1 G Lect 11M Binary outcomes in psychology Can Binary Outcomes Be Studied Using OLS Multiple Regression? Transforming the binary outcome Logistic.
Following the roman soldiers Cohort studies FETP India.
Measures of disease frequency (I). MEASURES OF DISEASE FREQUENCY Absolute measures of disease frequency: –Incidence –Prevalence –Odds Measures of association:
Understanding study designs through examples Manish Chaudhary MPH (BPKIHS)
Assessing Survival: Cox Proportional Hazards Model Peter T. Donnan Professor of Epidemiology and Biostatistics Statistics for Health Research.
Analysis of Complex Survey Data
Research Design: RCT and Cohort Studies John Q. Wong, MD, MSc 22 Jun 2010.
Copyright restrictions may apply A Randomized Trial of Nebulized 3% Hypertonic Saline With Epinephrine in the Treatment of Acute Bronchiolitis in the Emergency.
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND PANCREATIC CANCER RISK: A NESTED CASE-CONTROL STUDY Marie Bradley, Carmel Hughes, Marie Cantwell and Liam Murray.
Absolute, Relative and Attributable Risks. Outcomes or differences that we are interested in:  Differences in means or proportions  Odds ratio (OR)
7 Regression & Correlation: Rates Basic Medical Statistics Course October 2010 W. Heemsbergen.
Multiple Choice Questions for discussion
Measuring Associations Between Exposure and Outcomes.
Evidence-Based Medicine 4 More Knowledge and Skills for Critical Reading Karen E. Schetzina, MD, MPH.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2014.
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
Lecture 3 Survival analysis.
EPI 811 – Work Group Exercise #2 Team Honey Badgers Alex Montoye Kellie Mayfield Michele Fritz Anton Frattaroli.
Cardiovascular Disease & Mortality in Diabetes Stephen Fava MD, MRCP(UK), FEFIM, FACP, FRCP (Lond), MPhil (Malta), PhD (Exeter) Consultant Physician, Diabetologist.
Kia Ora!. November 2009 Tanzania Cohort Event Monitoring Prescription event monitoring (PEM) Dr. David Coulter formerly Research Associate Professor Intensive.
Overview of Issues for Psychopharmacological Drugs Advisory Committee June 16, 2003 WBC Monitoring for Clozapine Judith A. Racoosin, MD, MPH Safety Team.
RELATIVE TOXICITY OF CITALOPRAM AND OTHER SSRIs IN OVERDOSE GK Isbister 1,2, IM Whyte 1,2, AH Dawson 1,2 1 Department of Clinical Toxicology, Newcastle.
Assessing Survival: Cox Proportional Hazards Model
Design and Analysis of Clinical Study 11. Analysis of Cohort Study Dr. Tuan V. Nguyen Garvan Institute of Medical Research Sydney, Australia.
CTD, Safety Tanja Braakman Genzyme Europe BV Pharmacovigilance Department.
EBCP. Random vs Systemic error Random error: errors in measurement that lead to measured values being inconsistent when repeated measures are taken. Ie:
Changes in Renal Function in Patients Treated with Tenofovir DF (TDF) Compared to Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Joel E. Gallant,
Critical Appraisal of an Article on HARM. Clinical Question Is there potential harm after administering allopurinol in patients with gout and azotemia?
Predicting toxicity for patients with advanced Gastrointestinal Stromal Tumors (GIST) treated with imatinib mesylate : an EORTC/ISG/AGITG randomized trial.
April 4 Logistic Regression –Lee Chapter 9 –Cody and Smith 9:F.
Antiretroviral Pharmacovigilance Training Course Dar es Salaam, United Republic of Tanzania 23 rd – 28 th November 2009.
Magnus Wallberg Senior Systems Architect M Sc Engineering Physics Dar Es Salaam November 26 th, 2009 Tools for Pharmacovigilance.
Lipoatrophy and lipohypertrophy are independently associated with hypertension: the effect of lipoatrophy but not lipohypertrophy on hypertension is independent.
Sample Size August, 2007 Charles E. McCulloch Professor and Head, Division of Biostatistics Department of Epidemiology and Biostatistics.
Design and Analysis of Clinical Study 2. Bias and Confounders Dr. Tuan V. Nguyen Garvan Institute of Medical Research Sydney, Australia.
Measures of Association Intermediate Epidemiology.
RATES AND RISK Daniel E. Ford, MD, MPH Johns Hopkins School of Medicine Introduction to Clinical Research July 12, 2010.
Assessing Binary Outcomes: Logistic Regression Peter T. Donnan Professor of Epidemiology and Biostatistics Statistics for Health Research.
Measures of Association and Impact Michael O’Reilly, MD, MPH FETP Thailand Introductory Course.
Safety of Cyclooxygenase-2 (COX-2) inhibitors, Valdecoxib and Parecoxib, versus Placebo for Post CABG Pain Management Presented at American College of.
Top Trial Cheats Dr Rod Stables The Cardiothoracic Centre Liverpool UK No Conflicts of Interest to Declare.
Understanding Medical Articles and Reports Linda Vincent, MPH UCSF Breast SPORE Advocate September 24,
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
27 Nov 2009Dar es Salaam 1 David Coulter. Summary of content  What is a signal?  Recognising a signal  What can be achieved by you?  Clinical assessment.
1 Lecture 6: Descriptive follow-up studies Natural history of disease and prognosis Survival analysis: Kaplan-Meier survival curves Cox proportional hazards.
Describing the risk of an event and identifying risk factors Caroline Sabin Professor of Medical Statistics and Epidemiology, Research Department of Infection.
Critical Appraisal of an Article on HARM. Clinical Question Is there potential harm after administering allopurinol in patients with gout and azotemia?
What pharmacovigilance can do for you! relationship assessment is a better concept 24 Nov Dar es Salaam.
BC Jung A Brief Introduction to Epidemiology - XIII (Critiquing the Research: Statistical Considerations) Betty C. Jung, RN, MPH, CHES.
Measures of Disease Frequency
Logistic Regression. Linear regression – numerical response Logistic regression – binary categorical response eg. has the disease, or unaffected by the.
BIOSTATISTICS Lecture 2. The role of Biostatisticians Biostatisticians play essential roles in designing studies, analyzing data and creating methods.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
III. Measures of Morbidity: Morbid means disease. Morbidity is an important part of community health. It gives an idea about disease status in that community.
Meta-analysis of observational studies Nicole Vogelzangs Department of Psychiatry & EMGO + institute.
Measures of disease frequency Simon Thornley. Measures of Effect and Disease Frequency Aims – To define and describe the uses of common epidemiological.
26 Nov 2009 Dar es Salaam 1 Selecting the cohort David Coulter.
Rory M Marks, John Z Ayanian, Brahmajee K Nallamothu
Instructional Objectives:
Annals of Internal Medicine • Vol. 167 No. 12 • 19 December 2017
ASPIRE CLASS 6: Interpreting Results and Writing an Abstract
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
Risk Ratio A risk ratio, or relative risk, compares the risk of some health-related event such as disease or death in two groups. The two groups are typically.
Presentation transcript:

27 Nov 2009 Dar es Salaam 1 CEM analyses

27 Nov Dar es Salaam

What are we trying to measure? First, the risks associated with each ARV regimen First, the risks associated with each ARV regimen Each regimen will be treated like a single drug Each regimen will be treated like a single drug Second, the risks associated with individual drugs Second, the risks associated with individual drugs 27 Nov Dar es Salaam

27 Nov Dar es Salaam Approach Keep it simple Keep it simple most of the important results can be revealed by simple measures most of the important results can be revealed by simple measures Keep it accurate Keep it accurate clean, quality data clean, quality data controlled at input controlled at input Example: variation in spelling Example: variation in spelling

27 Nov Dar es Salaam Small things 1 Rates Rates What to do with drop-outs? What to do with drop-outs? Choosing the denominator Choosing the denominator total cohort includes drop-outs total cohort includes drop-outs demographics demographics total follow-up questionnaires returned total follow-up questionnaires returned general rates eg rates of events; reactions & incidents general rates eg rates of events; reactions & incidents Sites / regions Sites / regions Total per question answered Total per question answered Rate per data element eg traditional meds, TB Rate per data element eg traditional meds, TB

Small things 2 Examples of rates Overall reporting rate (response rate) Total cohort enrolled = 8432 Total follow-up forms received = 6998 Reporting rate = 6998/8432 = 83% Rates of events Total follow-up forms received = 6998 Total patients with oral candidiasis = 843 Rate of oral candidiasis = 843/6998 = 12% 27 Nov Dar es Salaam

Small things 3 Examples of rates Rates per total question answered for use of traditional medicines Rates per total question answered for use of traditional medicines Total follow-up forms received = 6998 Total follow-up forms received = 6998 Total TM questions answered = 5432 Total TM questions answered = 5432 Total answered ‘Yes’ = 3954 Total answered ‘Yes’ = 3954 Rate of use of traditional medicines = 3954/5432 = 73% Rate of use of traditional medicines = 3954/5432 = 73% 27 Nov Dar es Salaam

Small things 4 Calculation of risk The rate of occurrence of an event in the exposed cohort is a measure of absolute risk The rate of occurrence of an event in the exposed cohort is a measure of absolute risk Attributable risk: this is a measure of the increased risk associated with the medicine. It is calculated as follows: Attributable risk: this is a measure of the increased risk associated with the medicine. It is calculated as follows: rate in the exposed cohort minus rate in the exposed cohort minus rate before exposure (in the control period) rate before exposure (in the control period) 27 Nov Dar es Salaam

27 Nov Dar es Salaam Small things 4 Doses Doses Analyses are done on the total daily dose Analyses are done on the total daily dose Total daily dose x weekly e.g. Total daily dose x weekly e.g. 300mg 3 x weekly 300mg 3 x weekly Or 100mg 7 x weekly Or 100mg 7 x weekly Duration Duration Duration in days Duration in days 1 m = 30 days 1 m = 30 days 1 y = 365 days 1 y = 365 days Between x & y –take mid-point Between x & y –take mid-point

27 Nov Dar es Salaam Data manipulation Collation summary of reporting rates for males, females and totals; summary of reporting rates for males, females and totals; age/sex profiles of the cohort; age/sex profiles of the cohort; patient numbers by region or site; patient numbers by region or site; event profiles by clinical category; event profiles by clinical category; within a clinical category within a clinical category reactions & incidents reactions & incidents

27 Nov Dar es Salaam

27 Nov Dar es Salaam IMMP example –COX-2 Age & sex CelecoxibRofecoxib Mean6358 Mode5953 <40 years 6.9%12.6% Highly significant 70+ years 32.7%25.7% Highly significant Women61.6%60.5%

27 Nov Dar es Salaam Celecoxib dose mg/no./%

27 Nov Dar es Salaam

27 Nov Dar es Salaam Event profiles CelecoxibRofecoxib Odds Ratio Circulatory 315 (17%) 214 (20%) NS Alimentary 302 (17%) 218 (20%) 0.8 (0.66,0.97) Died 293 (16%) 179 (16%) Skin 160 (9%) 59 (5%) 1.7 ( ) Respiratory 108 (6%) 54 (5%) Psychiatric 88 (5%) 49 (5%) Renal 72 (4%) 46 (4%)

27 Nov 2009 Dar es Salaam 16 Events collation

27 Nov Dar es Salaam Event collations Look Carefully

27 Nov 2009 Dar es Salaam 18 Understanding the dictionary

27 Nov Dar es Salaam Examples Annex 8 events collation Annex 8 events collation Annex 12 eye events with signal Annex 12 eye events with signal Annex 11 deaths Annex 11 deaths Annex 13 concomitant medicines Annex 13 concomitant medicines

27 Nov Dar es Salaam Risk Risk calculation Risk calculation Relative risk (rate ratio) Relative risk (rate ratio) Rate of A / rate of B = relative risk Rate of A / rate of B = relative risk Confidence intervals Confidence intervals Risk factors eg age Risk factors eg age RR RR Multiple logistic regression Multiple logistic regression

Risks of individual drugs Compare events before and after drug substitutions with the patients acting as their own controls eg Compare events before and after drug substitutions with the patients acting as their own controls eg d4t(30)-3TC-NVP to d4t(30)-3TC-EFV d4t(30)-3TC-NVP to d4t(30)-3TC-EFV Compare events between regimens where substitutions have taken place Compare events between regimens where substitutions have taken place Use multiple logistic regression to test each drug as a risk factor for events of interest Use multiple logistic regression to test each drug as a risk factor for events of interest Large database needed for these analyses (pooled international data) Large database needed for these analyses (pooled international data) 27 Nov Dar es Salaam

27 Nov Dar es Salaam Life table (survival) analysis Helps to characterise a reaction Helps to characterise a reaction time to onset time to onset spread of onset times spread of onset times Testing a possible signal Testing a possible signal

Statistical programmes CemFlow CemFlow automated outputs automated outputs MedCalc MedCalc free for 25 sessions free for 25 sessions 27 Nov Dar es Salaam

27 Nov Dar es Salaam Don’t be afraid! of statistics